8-K: Azenta Reports FY26 Results, Guides FY27 Growth

Azenta announced its fourth quarter and full fiscal year 2026 results, highlighting 5% year-over-year revenue growth and providing guidance for fiscal year 2027 with expected revenue between $648-$660 million and adjusted EBITDA margin expansion.

Summary

• Azenta reported fourth quarter fiscal year 2026 revenue of $167 million, a 5% increase year-over-year, with organic revenue up 2%.
• Full fiscal year 2026 revenue reached $622 million, also a 5% increase year-over-year, with organic revenue up 2%.
• The company completed the sale of B Medical Systems, which is now reflected as discontinued operations.
• For fiscal year 2027, Azenta expects total reported revenue between $648 million and $660 million, with organic revenue growth projected at 3% to 5%.
• Fiscal year 2027 adjusted EBITDA margin is anticipated to expand by 200 to 250 basis points year-over-year.
• The company repurchased $118.2 million of common stock during fiscal year 2026 under its $250 million repurchase program.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but cautiously optimistic report, with revenue growth and strategic acquisitions showing promise, but offset by a significant goodwill impairment and a decrease in adjusted EBITDA margin.

Positives

• Revenue from continuing operations increased by 5% year-over-year for both the fourth quarter ($167M vs $159M) and the full fiscal year ($622M vs $594M).
• Organic revenue growth was 2% for both the fourth quarter and the full fiscal year.
• Sample Management Solutions showed strong performance with 9% revenue growth in Q4 and 6% in FY26.
• Adjusted diluted EPS from continuing operations increased by 33% in the fourth quarter ($0.28 vs $0.21).
• The company expects significant adjusted EBITDA margin expansion of 200-250 basis points in FY27.
• Free cash flow is expected to improve by approximately 25% in FY27 compared to FY26.
• Acquisition of SynPlexity Inc. is expected to expand gene synthesis capabilities.
• Entered into Elegen Agreements to expand gene synthesis capabilities, with potential capital deployment of $32M to $71M.

Negatives

• GAAP net loss from continuing operations was $157.9 million for the full fiscal year 2026, a significant decrease from a net income of $24.5 million in fiscal year 2025.
• A non-cash goodwill impairment charge of $149 million was recorded in fiscal year 2026.
• Adjusted EBITDA from continuing operations decreased by 7% in the fourth quarter ($19.4M vs $21M) and 12% for the full fiscal year ($58.3M vs $66.3M).
• Adjusted EBITDA margin from continuing operations decreased by 140 basis points in the fourth quarter (11.6% vs 13.0%) and 180 basis points for the full fiscal year (9.4% vs 11.2%).
• Organic revenue in Multiomics declined by 1% year-over-year in the fourth quarter.
• Gross margin decreased by 130 basis points year-over-year for the full fiscal year (44.2% vs 45.5%).
• Operating expenses increased by 51% year-over-year for the full fiscal year, largely due to the goodwill impairment charge.

Risks

• The company's ability to successfully implement, integrate, and commercialize its strategic investments, including the Elegen agreements and SynPlexity acquisition, and realize their anticipated benefits.
• Risks associated with future capital deployment and other obligations under the Elegen agreements.
• The ability to achieve anticipated revenue, margin, cost, and productivity improvements.
• Changes in customer demand, purchasing behavior, or funding conditions in the markets the company serves.
• Macroeconomic, geopolitical, or regulatory developments.
• Foreign currency fluctuations.
• Supply chain disruptions.
• Competitive dynamics.

Future Outlook

For fiscal year 2027, Azenta projects total reported revenue from continuing operations to be between $648 million and $660 million. Total organic revenue growth is expected to range from 3% to 5% year-over-year. Organic revenue for Sample Management Solutions is expected to grow mid-single-digits, and for Multiomics, low-single-digits. The company anticipates adjusted EBITDA margin expansion of 200 to 250 basis points year-over-year, inclusive of an expected dilution of 100 basis points from the Elegen agreements and SynPlexity acquisition. Free cash flow is expected to improve approximately 25% relative to fiscal year 2026.

Management Comments

• "We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year."
• "Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency."
• "Fiscal 2027 is about consistent execution and accelerating performance. We are focused on driving organic growth, expanding profitability and cash generation, and executing on our strategic initiatives."

Industry Context

StockSavvy.ai notes that Azenta's focus on life sciences solutions, particularly in sample management and multiomics, aligns with broader industry trends of increasing demand for advanced research and development tools. The strategic acquisitions of Elegen and SynPlexity indicate a move to bolster capabilities in gene synthesis, a critical area for drug discovery and therapeutic development, suggesting an effort to capture more value in the rapidly evolving biotech and pharmaceutical sectors.

Comparison to Industry Standards

• The reported 5% year-over-year revenue growth for FY26 is moderate compared to some high-growth biotech or specialized life science tool companies, but aligns with a more mature segment of the industry.
• The projected 3-5% organic revenue growth for FY27 is in line with expectations for companies in the life sciences services sector that are not in hyper-growth phases.
• The planned 200-250 basis point expansion in adjusted EBITDA margin for FY27 is a positive indicator of operational efficiency improvements, which is a key focus for many companies in this sector aiming to balance growth with profitability.
• The significant goodwill impairment charge of $149 million in FY26 is a substantial event that would be scrutinized against industry peers; such charges often signal overpayment in prior acquisitions or a significant decline in the value of acquired assets, which can impact investor confidence.

Stakeholder Impact

• Shareholders: The goodwill impairment and decreased adjusted EBITDA may negatively impact share price in the short term, while the FY27 guidance for revenue growth and margin expansion offers potential for future returns.
• Employees: Strategic initiatives and acquisitions may lead to restructuring or integration efforts, potentially impacting roles and responsibilities.
• Customers: Expansion of gene synthesis capabilities through Elegen and SynPlexity could lead to enhanced product and service offerings.
• Creditors: The company's liquidity position of $506 million in cash, cash equivalents, and marketable securities provides a buffer for debt obligations.

Next Steps

• Focus on consistent execution and accelerating performance in fiscal year 2027.
• Drive organic growth across business segments.
• Expand profitability and cash generation.
• Execute on strategic initiatives, including integration and commercialization of Elegen and SynPlexity.
• Manage capital deployment under the Elegen agreements, including potential future equipment purchases and license conversion.

Key Dates

Recommendation

The company shows signs of recovery with revenue growth and a positive outlook for FY27, including margin expansion and strategic acquisitions. However, the significant goodwill impairment, decrease in full-year adjusted EBITDA, and mixed performance in the Multiomics segment warrant a cautious approach. The 'hold' recommendation reflects the balance between potential upside from strategic initiatives and the risks associated with execution and market conditions.

Keywords

life sciences solutions, sample management, multiomics, gene synthesis, revenue growth, EBITDA margin, financial results, acquisitions